Pentraxin-2 is Associated with Renal Fibrosis in Patients Undergoing Renal Biopsy

Abstract

OBJECTIVES: Progressive renal disease is characterized by histological changes in the kidney and fibrosis is a common outcome. Renal biopsy is the only diagnostic tool to evaluate these histopathological changes. Pentraxin-2 (PTX-2) is an anti-inflammatory constitutive plasma protein associated with the innate immune system. Recently, as a biomarker, the circulating level of PTX-2 is shown to be decreased in chronic fibrotic diseases. In this study, we aimed to investigate the relationship between renal fibrosis severity and serum PTX-2 levels in patients undergoing renal biopsy. METHODS: This cross-sectional study included 45 patients and 16 healthy individuals (HIs). The severity of renal fibrosis was evaluated according to the Banff and Sethi scoring systems by the same pathologist. PTX-2 was measured by an enzyme-linked immunosorbent assay and compared with the demographical, clinical, biochemical, and histopathological data of the patients and HIs. RESULTS: PTX-2 levels were lower in the biopsy group than in the HI group ( p =0.12). Patients with moderate renal fibrosis had significantly lower serum PTX-2 levels than those in patients with minimal and mild fibrosis ( p =0.017 and p =0.010, respectively). PTX-2 concentrations were correlated with serum albumin (r=0.30, p =0.016), and were negatively correlated with serum creatinine levels (rho=-0.42, p =0.01) and body mass index (r=-0.32, p =0.011). CONCLUSIONS: The results indicated that PTX-2 levels are significantly lower in patients with renal fibrosis than HIs, and declining further in patients with severe fibrosis.

Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis

“…Blood lysyl oxidase (LOX), human epididymis protein 4 (HE4), and pentraxin-2, have the potential to assess renal brosis, but they are easily affected by other brotic diseases (liver brosis, pulmonary brosis, etc.) [15][16][17]. Non-invasive imaging examinations such as B-ultrasound can only indirectly re ect renal brosis through renal anatomical changes, making it di cult to determine the degree of renal brosis early and accurately.…”

Antifibrotic Agents for the Management of CKD: A Review

“…PRM-151 is a recombinant human pentraxin 2/serum amyloid P protein. Serum pentraxin 2 levels are low in fibrotic conditions, including kidney fibrosis, and recombinant human pentraxin 2 delays CKD progression in Alport mice, enhancing lifespan and decreasing kidney inflammation and fibrosis (51,52). Reduced activator protein 1 (AP-1)-driven inflammation is a key mechanism of action.…”